Livforsakringsbolaget Skandia Omsesidigt Purchases 124 Shares of Humana Inc. (NYSE:HUM)

Livforsakringsbolaget Skandia Omsesidigt grew its position in Humana Inc. (NYSE:HUM) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,427 shares of the insurance provider’s stock after acquiring an additional 124 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Humana were worth $2,029,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Daiwa Securities Group Inc. raised its stake in shares of Humana by 25.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 17,021 shares of the insurance provider’s stock valued at $7,792,000 after acquiring an additional 3,458 shares during the last quarter. Rakuten Securities Inc. bought a new position in Humana in the 4th quarter valued at $25,000. Tyche Wealth Partners LLC bought a new stake in shares of Humana during the fourth quarter worth $271,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Humana by 2.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,880 shares of the insurance provider’s stock valued at $21,004,000 after acquiring an additional 1,237 shares during the last quarter. Finally, Everence Capital Management Inc. increased its position in Humana by 4.0% in the fourth quarter. Everence Capital Management Inc. now owns 4,370 shares of the insurance provider’s stock worth $2,001,000 after purchasing an additional 170 shares during the period. Institutional investors own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

HUM has been the subject of several analyst reports. StockNews.com cut shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. Royal Bank of Canada dropped their target price on shares of Humana from $507.00 to $415.00 and set an “outperform” rating for the company in a research report on Friday, January 26th. Argus lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Wells Fargo & Company cut their target price on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research note on Monday, April 8th. Finally, Stephens decreased their target price on Humana from $550.00 to $430.00 and set an “overweight” rating for the company in a research report on Friday, January 26th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $465.42.

Humana Price Performance

HUM stock opened at $330.00 on Thursday. The stock has a 50-day moving average price of $344.41 and a two-hundred day moving average price of $425.71. The stock has a market cap of $39.81 billion, a PE ratio of 16.32, a price-to-earnings-growth ratio of 1.86 and a beta of 0.45. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana Inc. has a 1 year low of $299.23 and a 1 year high of $541.21.

Humana (NYSE:HUM) last released its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). The firm had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. Humana’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter last year, the company posted $1.62 EPS. Equities analysts forecast that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.07%. Humana’s dividend payout ratio (DPR) is presently 17.86%.

Insiders Place Their Bets

In other news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction on Tuesday, February 20th. The stock was purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.